BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prêtre V, Wicki A. Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy? Semin Cancer Biol 2018;48:70-7. [PMID: 28473255 DOI: 10.1016/j.semcancer.2017.04.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Lai H, Han J, Fu X, Ren Y, Li Z, You F. Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers 2022;14:3774. [DOI: 10.3390/cancers14153774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wu X, Xie W, Xie W, Wei W, Guo J. Beyond controlling cell size: functional analyses of S6K in tumorigenesis. Cell Death Dis 2022;13:646. [PMID: 35879299 DOI: 10.1038/s41419-022-05081-4] [Reference Citation Analysis]
3 Zhang W, Li L, Guo E, Zhou H, Ming J, Sun L, Hu G, Zhang L. Inhibition of PDK1 enhances radiosensitivity and reverses epithelial-mesenchymal transition in nasopharyngeal carcinoma. Head Neck 2022;44:1576-87. [PMID: 35394102 DOI: 10.1002/hed.27053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xie Y, Liu C, Zhang Y, Li A, Sun C, Li R, Xing Y, Shi M, Wang Q. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair. PLoS One 2021;16:e0258817. [PMID: 34665844 DOI: 10.1371/journal.pone.0258817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kang BW, Chau I. Molecular target: pan-AKT in gastric cancer. ESMO Open. 2020;5:e000728. [PMID: 32948630 DOI: 10.1136/esmoopen-2020-000728] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
6 Basu A, Lambring CB. Akt Isoforms: A Family Affair in Breast Cancer. Cancers (Basel) 2021;13:3445. [PMID: 34298660 DOI: 10.3390/cancers13143445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
7 Ikonomopoulou MP, Lopez-Mancheño Y, Novelle MG, Martinez-Uña M, Gangoda L, Pal M, Costa-Machado LF, Fernandez-Marcos PJ, Ramm GA, Fernandez-Rojo MA. LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin target in Tasmanian devil facial tumor disease. Cell Rep 2021;34:108851. [PMID: 33730574 DOI: 10.1016/j.celrep.2021.108851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Sang Y, Kong P, Zhang S, Zhang L, Cao Y, Duan X, Sun T, Tao Z, Liu W. SGK1 in Human Cancer: Emerging Roles and Mechanisms. Front Oncol 2020;10:608722. [PMID: 33542904 DOI: 10.3389/fonc.2020.608722] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
9 Jin HF, Wang JF, Song TT, Zhang J, Wang L. MiR-200b Inhibits Tumor Growth and Chemoresistance via Targeting p70S6K1 in Lung Cancer. Front Oncol 2020;10:643. [PMID: 32435616 DOI: 10.3389/fonc.2020.00643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
10 Mitz CA, Viloria-Petit AM. Contrasting effects of transforming growth factor β1 on programmed cell death of bovine mammary epithelial cell lines MAC-T and BME-UV1. J Dairy Sci 2020;103:5532-49. [PMID: 32229120 DOI: 10.3168/jds.2019-17460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, Tan AR, Aisner J, Moss RA, Lin H, Bertino JR, Gibbon D, Doyle LA, White EP, Stein MN. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2019;84:899-907. [PMID: 31463691 DOI: 10.1007/s00280-019-03919-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
12 Li X, Li Z, Wu X, Xiong Z, Yang T, Fu Z, Liu X, Tan X, Zhong F, Wan X, Wang D, Ding X, Yang R, Hou H, Li C, Liu H, Chen K, Jiang H, Zheng M. Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation. J Med Chem 2020;63:8723-37. [PMID: 31364850 DOI: 10.1021/acs.jmedchem.9b00855] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
13 Xie X, Lin J, Zhong Y, Fu M, Tang A. FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. Exp Ther Med 2019;18:1226-34. [PMID: 31316618 DOI: 10.3892/etm.2019.7672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wang D, Jin M, Zhao X, Zhao T, Lin W, He Z, Fan M, Jin W, Zhou J, Jin L, Zheng C, Jin H, Zhao Y, Li X, Ying L, Wang Y, Zhu G, Huang Z. FGF1ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation. Cell Death Dis 2019;10:464. [PMID: 31189876 DOI: 10.1038/s41419-019-1696-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
15 Ma Z, Liu D, Li W, Di S, Zhang Z, Zhang J, Xu L, Guo K, Zhu Y, Han J, Li X, Yan X. STYK1 promotes tumor growth and metastasis by reducing SPINT2/HAI-2 expression in non-small cell lung cancer. Cell Death Dis 2019;10:435. [PMID: 31164631 DOI: 10.1038/s41419-019-1659-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
16 Ochoa R, Rocha-Roa C, Marín-Villa M, Robledo SM, Varela-M RE. Search of Allosteric Inhibitors and Associated Proteins of an AKT-like Kinase from Trypanosoma cruzi. Int J Mol Sci 2018;19:E3951. [PMID: 30544836 DOI: 10.3390/ijms19123951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schmidt KM, Dietrich P, Hackl C, Guenzle J, Bronsert P, Wagner C, Fichtner-Feigl S, Schlitt HJ, Geissler EK, Hellerbrand C, Lang SA. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis. Neoplasia 2018;20:1198-208. [PMID: 30404068 DOI: 10.1016/j.neo.2018.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
18 Yahiro Y, Maeda S, Shinohara N, Jokoji G, Sakuma D, Setoguchi T, Ishidou Y, Nagano S, Komiya S, Taniguchi N. PEG10 counteracts signaling pathways of TGF-β and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells. J Bone Miner Metab 2019;37:441-54. [PMID: 30094509 DOI: 10.1007/s00774-018-0946-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Phyu SM, Smith TAD. Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation. Invest New Drugs 2019;37:424-30. [PMID: 30056610 DOI: 10.1007/s10637-018-0642-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
20 Chen GH, Xu CS, Zhang J, Li Q, Cui HH, Li XD, Chang LP, Tang RJ, Xu JY, Tian XQ, Huang PS, Xu J, Jin C, Yang YJ. Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1. Front Pharmacol 2017;8:775. [PMID: 29163161 DOI: 10.3389/fphar.2017.00775] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
21 Hydbring P, Castell A, Larsson LG. MYC Modulation around the CDK2/p27/SKP2 Axis. Genes (Basel) 2017;8:E174. [PMID: 28665315 DOI: 10.3390/genes8070174] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]